Search clinical trials for: BT8009

Total 29 results

Garnet BioTherapeutics, Inc.

Completed

Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery

Scar Formation

United States
Bio-Thera Solutions

Terminated

Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer

Advanced Solid Cancer

China
Bio-Thera Solutions

Unknown

A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor

Solid Tumor

China
Medical University of Vienna

Completed

BT200 in Hereditary Bleeding Disorders

Hemophilia A | Von Willebrand Diseases

Austria
Inhibikase Therapeutics, Inc.

Recruiting

A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease

Parkinson Disease

United States
Lpath, Inc.

Terminated

A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Inhibikase Therapeutics, Inc.

Completed

A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients

Parkinson Disease | Healthy Elderly

United States
Lpath, Inc.

Unknown

Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration

Neovascular Age Related Macular Degeneration

United States
Zhuhai Beihai Biotech Co., Ltd

Recruiting

A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer

Solid Tumor, Adult

China
BicycleTx Limited

Recruiting

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Carcinoma, Non-Small-Cell Lung | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Ovarian Neoplasm | Urinary Bladder Neoplasm

United States, United Kingdom, France, Spain, Italy, Canada
Lpath, Inc.

Completed

Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors (ASONEP)

Solid Tumors

United States
Bio-Thera Solutions

Not yet recruiting

A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Lpath, Inc.
Pfizer

Terminated

iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV) (PED)

Pigment Epithelial Detachment

United States
BicycleTx Limited

Recruiting

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Metastatic Urothelial Cancer

United States
Bioverativ, a Sanofi company
Assign Data Management and Biostatistics GmbH; Quest Diagnostics-Nichols Insitute and other collaborators

Completed

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders (BIVV009-01)

End-stage Renal Disease (ESRD) | Cold Agglutinin Disease (CAD) | Bullous Pemphigoid (BP) | Warm Autoimmune Hemolytic Anemia (WAIHA)

Austria
HK inno.N Corporation

Recruiting

Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)

COVID-19

Korea, Republic of
Bio-Thera Solutions

Not yet recruiting

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection

Advanced Solid Tumors
Zhuhai Beihai Biotech Co., Ltd

Completed

A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours

Solid Tumours | Bioequivalence | Docetaxel

India
Bio-Thera Solutions

Recruiting

Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009

Locally Advanced/Metastatic Solid Tumours

China
Pearl Therapeutics, Inc.

Withdrawn

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease
Bio-Thera Solutions

Unknown

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer

China
Bio-Thera Solutions
Zhejiang Tumor Hospital

Recruiting

To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Band Therapeutics

Completed

A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers

Intracranial Arteriosclerosis | Cerebrovascular Stroke | Large-Artery Atherosclerosis (Embolus/Thrombosis)

Austria
Bio-Thera Solutions

Unknown

A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients

HER2-Positive Solid Tumors

China
Bio-Thera Solutions

Recruiting

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Advanced Solid Tumors

China
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Chronic Obstructive Pulmonary Disorder

United States, Austria, Belgium, Canada, Denmark, Germany, Italy, Spain, Sweden, United Kingdom, Peru, Brazil, South Africa, Argentina, Russian Federation, Mexico, Puerto Rico, Chile, Norway
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

COPD

United States

3

Subscribe